Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Penumbra Inc is a medical devices business based in the US. Penumbra shares (PEN) are listed on the NYSE and all prices are listed in US Dollars. Penumbra employs 3,800 staff and has a trailing 12-month revenue of around $806.4 million.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Social traders
| Latest market close | $191.82 |
|---|---|
| 52-week range | $114.87 - $290.36 |
| 50-day moving average | $163.64 |
| 200-day moving average | $187.10 |
| Wall St. target price | $211.25 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.18 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $191.82 from 2022-09-29
| 1 week (2022-09-23) | 3.72% |
|---|---|
| 1 month (2022-09-01) | 15.37% |
| 3 months (2022-07-01) | 52.60% |
| 6 months (2022-03-31) | -13.65% |
| 1 year (2021-10-01) | -27.09% |
|---|---|
| 2 years (2020-10-01) | 0.75% |
| 3 years (2019-10-01) | 42.29% |
| 5 years (2017-09-29) | 112.43% |
| Revenue TTM | $806.4 million |
|---|---|
| Gross profit TTM | $475.4 million |
| Return on assets TTM | -1.98% |
| Return on equity TTM | -2.46% |
| Profit margin | -2.41% |
| Book value | $25.61 |
| Market capitalisation | $7 billion |
TTM: trailing 12 months
We're not expecting Penumbra to pay a dividend over the next 12 months.
Penumbra's shares were split on a 10:1 basis on 15 November 2014. So if you had owned 1 share the day before before the split, the next day you'd have owned 10 shares. This wouldn't directly have changed the overall worth of your Penumbra shares – just the quantity. However, indirectly, the new 90% lower share price could have impacted the market appetite for Penumbra shares which in turn could have impacted Penumbra's share price.
Over the last 12 months, Penumbra's shares have ranged in value from as little as $114.865 up to $290.36. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Penumbra's is 0.666. This would suggest that Penumbra's shares are less volatile than average (for this exchange).
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
